Thursday 24 March
16:30-18:45
Session 6: Novel approaches in cancer therapy
Chairs: Dirk Nettelbeck, DKFZ, Heidelberg; Michael Morgan, Hannover Medical School
16:30 - 16:45 Dirk Nettelbeck,DKFZ, Heidelberg, Michael Morgan, Hannover Medical School
Novel approaches in cancer therapy – current status in a nutshell
INV16 16:45-17:15
Guy Ungerechts, NCT Heidelberg ⓘ
Immunovirotherapy for Cancer
INV17 17:15-17:45
Benjamin Rengstl, BionNTech, Mainz ⓘ
BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors
INV18 17:45-18:15
Martin Sauer, Hannover Medical School ⓘ
Off the shelf cellular immunotherapy: Dream or Necessity?
OR08 18:15-18:30
Ulrike Naumann, University of Tübingen
Immunogenic cell death determines the therapeutic impact of the oncolytic adenovirus XVir-N-31 in glioma and induces abscopal effects in combination with immune checkpoint inhibition
OR09 18:30-18:45
Maria Silvia Ramon Azcona, Medical Center – University of Freiburg
Sustained modulation of immune checkpoint expression in CAR T cells upon transient exposure to a designer epigenome modifier